Rubius Therapeutics (RUBY) Stock Analysis

What Rubius Therapeutics does

Rubius Therapeutics, Inc. is a clinical-stage biopharmaceutical entity focused on developing innovative red cell therapeutics (RCTs) to combat severe diseases. Its pipeline features RTX-240 and RTX-224, both advancing as treatments for solid tumor cancers, alongside RTX-aAPC for various other oncological conditions. The company is also progressing RTX-321 for HPV-positive tumors and RTX-T1D for the management of type 1 diabetes. Founded in 2013, Rubius Therapeutics is headquartered in Cambridge, Massachusetts.

Key metrics

ETFs linked to RUBY

Broad-market and Healthcare sector ETFs an investor holding Rubius Therapeutics is often also exposed to. Open an ETF page to see its actual top holdings.

PortView Portfolio Insights

PortView analyzes how RUBY fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Similar companies

Frequently asked questions

What is the ticker symbol for Rubius Therapeutics?

Rubius Therapeutics trades under the ticker RUBY on NASDAQ.

Which exchange is RUBY listed on?

RUBY is listed on NASDAQ.

What sector does Rubius Therapeutics operate in?

Rubius Therapeutics is classified in the Healthcare sector (Biotechnology industry).

How can PortView help analyze RUBY in a portfolio?

PortView shows RUBY's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.